Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04596150 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
A Phase 2 study, sponsored by CytomX Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT04596150 is a Phase 2 study that has completed, run by CytomX Therapeutics. The registered enrollment target is 125 participants.
The verdict
NCT04596150, a Phase 2 study, has completed, sponsored by CytomX Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
Interventions
- DRUG CX-2009
- DRUG CX-072
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2023-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04596150
The ClinicalTrials.gov registry entry for NCT04596150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CX-2009 is the first listed.
NCT04596150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04596150 about?
NCT04596150 is a clinical study titled "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer". A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
What is the current status of trial NCT04596150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2020-12-29. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT04596150?
The interventions under investigation include: CX-2009 (DRUG), CX-072 (DRUG).
Who is sponsoring clinical trial NCT04596150?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.